SBRT and camrelizumab delivered durable control in selected oligometastatic NSCLC

A prospective phase 2 trial in advanced non-small-cell lung cancer suggests that consolidative stereotactic body radiotherapy can be paired with PD-1 blockade to produce durable disease control in carefully selected patients with oligometastatic disease. After induction chemoimmunotherapy, patients with non-progressive, driver mutation-negative stage IV disease received SBRT to the primary tumor or metastatic lesions, followed by maintenance camrelizumab. The median progression-free survival reached 13.6 months, and median overall survival extended to 32.9 months, outcomes that sit above what would be expected from historical controls alone.

The design matters because this was not an unselected metastatic population. Eligibility required no more than five lesions in total, with distant metastases involving no more than three organs, and at least one lesion had to be technically suitable for SBRT. Patients had already completed four to six cycles of first-line chemoimmunotherapy without progression before entering the radiation phase. In practice, the study asked a narrow but clinically relevant question: can local ablation of residual disease deepen the response achieved with systemic immunotherapy in patients whose metastatic burden remains limited?

The answer appears biologically plausible. SBRT delivers large doses per fraction over a short course, which can induce immunogenic cell death, increase antigen presentation, and amplify T-cell priming through cGAS–STING-dependent type I interferon signaling. Those immune effects create a rational partner for PD-1 blockade, especially in tumors that have already shown sensitivity to induction treatment. The strategy also mirrors a broader clinical logic seen across solid tumors: once systemic therapy has reduced the disease burden to a small number of visible sites, consolidating those lesions may suppress the residual clones most likely to seed progression.

Survival outcomes were strongest when SBRT targeted the primary tumor

The trial enrolled 46 treated patients after screening 48 candidates. The cohort included 35 men and 11 women, with a median age of 64 years and a median follow-up of 24.4 months. A total of 49 lesions were irradiated, including 17 primary tumors and 32 metastatic lesions. In the full analysis set, the 2-year progression-free survival rate was 34.8%, and the 2-year overall survival rate was 74.1%. The objective response rate reached 34.8%.

One of the most clinically interesting signals came from the exploratory subgroup analysis. Patients who received SBRT to the primary tumor had a median progression-free survival of 33.1 months, compared with 12.2 months in those treated with metastatic-lesion SBRT. The hazard ratio favored primary-tumor treatment, with a nominal P value of 0.023. The separation may reflect more than a simple anatomic preference. The primary lesion can act as a dominant reservoir of viable disease and immunologic escape, so ablating it may exert a larger systemic effect than treating isolated metastatic deposits when the remaining tumor burden is small.

Still, the study was single-arm and nonrandomized. It cannot prove that radiotherapy itself produced the survival benefit, nor can it isolate the relative contribution of SBRT from induction chemoimmunotherapy and subsequent camrelizumab maintenance. The patient population was also highly selected, which likely enriched the cohort for favorable biology and treatment responsiveness.

Toxicity remained manageable, with cutaneous capillary endothelial proliferation most common

Safety outcomes were acceptable, particularly for a regimen that combined multi-modality treatment with immune checkpoint inhibition. Grade 3 or higher treatment-related adverse events occurred in 6 patients, representing 13.0% of the cohort. No grade 4 or higher treatment-related toxicities were observed. The most common adverse event was reactive cutaneous capillary endothelial proliferation, seen in 21 patients, or 46% of the treated group.

That toxicity pattern fits camrelizumab’s known safety profile. RCCEP has become one of the drug’s most recognizable immune-related adverse effects and often appears more as a distinctive biologic signature than as a classic dose-limiting organ toxicity. In a regimen that already included thoracic and metastatic radiation, the absence of grade 4 events is reassuring, but it does not eliminate concern about late pulmonary, esophageal, or cumulative tissue injury, especially when treatment fields broaden beyond a single lesion.

Local treatment selection remained individualized rather than randomized

Radiotherapy planning was intentionally personalized. After induction chemoimmunotherapy, lesion selection depended on response, number and size of residual sites, proximity to organs at risk, cumulative normal-tissue exposure, technical feasibility, and patient preference. When all residual disease could be treated safely within constraints, comprehensive irradiation was used. When lesion distribution or toxicity concerns made that impossible, treatment was limited to selected sites. In some cases, conventionally fractionated radiotherapy replaced SBRT when broader thoracic coverage was needed or dose constraints could not be met.

This flexibility reflects real-world radiation oncology, but it also introduces interpretive uncertainty. The treated lesions were not randomized, and the intensity of local therapy may have tracked with disease pattern, anatomy, and physician judgment. Such factors make it difficult to know whether the longer progression-free survival seen in the primary-tumor group arose from lesion biology, treatment selection, or both.

The biologic rationale for the combined approach remains strong. SBRT can release tumor antigens and reshape the immune microenvironment, while PD-1 blockade sustains the cytotoxic T-cell activity needed to maintain tumor control after local ablation. In a disease such as oligometastatic NSCLC, where the metastatic state is limited rather than diffuse, that pairing has a credible mechanistic basis. Even so, the current data support hypothesis generation rather than practice change.

Randomized testing will be needed before this strategy can be generalized

The trial offers a practical signal for patients with driver mutation-negative oligometastatic NSCLC who respond to induction chemoimmunotherapy but are not yet in progression. A median overall survival near 33 months and a 2-year survival rate above 70% are clinically meaningful in this setting, but they should be interpreted alongside the limits of the design. Historical comparison is vulnerable to selection bias, and the favorable outcomes may not reproduce in broader metastatic cohorts.

The study was registered in the Chinese Clinical Trial Registry as ChiCTR2100050165. Its publication strengthens the case for further randomized controlled trials that can determine whether SBRT adds survival benefit beyond modern systemic therapy and whether the choice of target lesion, especially primary tumor versus metastasis, changes the magnitude of benefit. Until such trials read out, the regimen remains an encouraging but unproven consolidation strategy for a narrowly defined group of patients.


Reporting by Dr. Revathy Mohan V.R., MBBS for Medicine World Foundation, with additional data provided by Frontiers in Immunology.
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA